Jazz Pharmaceuticals plc
JAZZ
$103.58
$5.805.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.06B | 4.07B | 3.99B | 3.91B | 3.84B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.06B | 4.07B | 3.99B | 3.91B | 3.84B |
| Cost of Revenue | 387.17M | 378.98M | 362.95M | 353.49M | 341.13M |
| Gross Profit | 3.68B | 3.69B | 3.63B | 3.56B | 3.50B |
| SG&A Expenses | 1.58B | 1.42B | 1.38B | 1.36B | 1.36B |
| Depreciation & Amortization | 626.03M | 627.31M | 619.96M | 617.39M | 614.23M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.40B | 3.28B | 3.19B | 3.20B | 3.17B |
| Operating Income | 662.21M | 793.37M | 799.35M | 711.53M | 669.73M |
| Income Before Tax | 361.29M | 468.69M | 396.55M | 295.68M | 237.88M |
| Income Tax Expenses | -120.91M | -91.43M | -66.61M | -99.25M | -92.92M |
| Earnings from Continuing Operations | 482.20 | 560.12 | 463.16 | 394.92 | 330.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 482.20M | 560.12M | 463.16M | 394.92M | 330.79M |
| EBIT | 662.21M | 793.37M | 799.35M | 711.53M | 669.73M |
| EBITDA | 1.32B | 1.45B | 1.45B | 1.36B | 1.31B |
| EPS Basic | 7.82 | 9.11 | 7.45 | 6.28 | 5.23 |
| Normalized Basic EPS | 4.35 | 5.54 | 5.50 | 4.45 | 3.86 |
| EPS Diluted | 7.50 | 8.79 | 7.10 | 5.82 | 4.85 |
| Normalized Diluted EPS | 4.13 | 5.32 | 5.13 | 4.02 | 3.47 |
| Average Basic Shares Outstanding | 245.81M | 247.37M | 249.41M | 251.11M | 252.22M |
| Average Diluted Shares Outstanding | 255.28M | 256.84M | 265.01M | 273.13M | 277.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |